This is a phase I, randomized, double-blind, parallel-group trial to compare Investigation Medicinal Product (IMP) MSB11022, US- Reference Product (RP), and EU- Reference Medicinal Product (RMP) (Humira®) in healthy subjects.
Inclusion Criteria: * Healthy male subjects and healthy female subjects of non-childbearing potential aged 18 to 55 years, inclusive. * Other protocol defined inclusion criteria could apply. Exclusion Criteria: * Concurrent or history infections such as opportunistic infections, including sepsis, pneumonia, and fungal infection. * Individuals with history of tuberculosis or diagnosed with tuberculosis by interview, chest X-ray examination, or interferon-gamma release assay. * Concurrent or history of demyelinating disease (multiple sclerosis, etc.). * Concurrent or history of congestive cardiac failure. * Concurrent or history of allergic symptoms such as asthma bronchial, drug-induced rash, and urticaria, which, in the judgment of the investigator, may affect participation in this clinical study. * Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory, and/or hematological function disorders, which, in the judgment of the investigator or any of the sub investigators, may affect participation in this clinical study. * Other protocol defined exclusion criteria could apply.